PHENYTOIN KINETICS IN SUBJECTS WITH OBESE, MUSCULAR, AND NORMAL BODY COMPOSITION

肥胖、肌肉发达和身体成分正常受试者的苯妥英动力学

• 批准号: 3741153
• 负责人: RONALD C. REED
• 金额: --
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3741153
• 关键词: body composition; body weight; dosage; drug metabolism; human subject; muscle; obesity; pharmacokinetics; phenytoin

Phenytoin pharmacokinetics is well known for normal body composition. These change with increasing obesity; i.e. distribution volume is increased, elimination half-life is prolonged, but total clearance is unchanged. Subj. with greater than average body wt., but body fat content below 10% represent a sub-group that has not been studied. The purpose is to determine if body composition (% fat + % lean tissue) may be a better predictor of phenytoin dose requirements than total body weight. This may apply to drugs in general.

苯妥英的药代动力学是众所周知的正常身体组成。 这些随着肥胖的增加而变化;即分布体积是 增加，消除半衰期延长，但总清除率 不变 体重高于平均体重的受试者，但是身体脂肪 含量低于10%代表尚未研究的亚组。 的 目的是确定身体组成（%脂肪+ %瘦肉组织）是否可以 比全身更能预测苯妥英剂量需求 重量. 这可能适用于一般药物。